Phrontline Biopharma develops innovative antibody-drug conjugates (ADCs) focused on oncology therapies.
phrontlinebio.comHangzhou, ChinaBiotechFounded 2022
4 sources · checked 6 times, last 10h ago
The company release fixes the announcement date at November 13; the news index displays November 16. The approximately $100 million is a twelve-month total that includes the earlier $60 million Pre-A+ round.
2 sources
Source 1, the company's release, dates the announcement November 25, 2025; Source 2 gives a November 24 dateline. The company's release controls.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A | $40M ~$100M to date | 2026-11-13 | Decheng Capital, Oriza Seed Venture Capital | No recent discussion |
4 sources · checked 6 times, last 10h ago [ VERIFIED ] read against 4 sources The company release fixes the announcement date at November 13; the news index displays November 16. The approximately $100 million is a twelve-month total that includes the earlier $60 million Pre-A+ round. | ||||
Found on X with Firecrawl search
Phrontline Biopharma builds next-generation antibody-drug conjugate medicines for cancer patients, using dual-targeting antibodies and dual-payload designs to improve delivery and overcome resistance.
Phrontline is pursuing bispecific and dual-payload ADCs because its pages say conventional single-target, single-payload ADCs are limited by tumor heterogeneity, drug resistance, and durability, while TJ101 and TJ102 have reached clinical development. The latest financing report says its nearly USD 40 million Series A, following the $60 million Pre-A+ round, will fund clinical development, IND filings, a new payload platform, and international collaborations.
Checked against 9 sources 5d ago
| Pre-A Pre‑A+ financing round [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $60M | 2025-11-25 | Lapam Capital | No recent discussion |
2 sources [ VERIFIED · CORRECTED ] read against 2 sources Source 1, the company's release, dates the announcement November 25, 2025; Source 2 gives a November 24 dateline. The company's release controls. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]2 pages read: phrontlinebio.com, prnewswire.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 2 sources·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||